|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lai CH and Lau WY: Gallbladder cancer - a
comprehensive review. Surgeon. 6:101–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goetze TO: Gallbladder carcinoma:
Prognostic factors and therapeutic options. World J Gastroenterol.
21:12211–12217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Unger S, Böhm D, Kaiser FJ, Kaulfuss S,
Borozdin W, Buiting K, Burfeind P, Böhm J, Barrionuevo F, Craig A,
et al: Mutations in the cyclin family member FAM58A cause an
X-linked dominant disorder characterized by syndactyly, telecanthus
and anogenital and renal malformations. Nat Genet. 40:287–289.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guen VJ, Gamble C, Flajolet M, Unger S,
Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L and
Colas P: CDK10/cyclin M is a protein kinase that controls ETS2
degradation and is deficient in STAR syndrome. Proc Natl Acad Sci
USA. 110:pp. 19525–19530. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorns E, Turner NC, Elliott R, Syed N,
Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ and Ashworth A:
Identification of CDK10 as an important determinant of resistance
to endocrine therapy for breast cancer. Cancer Cell. 13:91–104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leman ES, Magheli A, Yong KM, Netto G,
Hinz S and Getzenberg RH: Identification of nuclear structural
protein alterations associated with seminomas. J Cell Biochem.
108:1274–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu JH, Zhong XY, Zhang WG, Wang ZD, Dong
Q, Tai S, Li H and Cui YF: CDK10 functions as a tumor suppressor
gene and regulates survivability of biliary tract cancer cells.
Oncol Rep. 27:1266–1276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong XY, Xu XX, Yu JH, Jiang GX, Yu Y,
Tai S, Wang ZD and Cui YF: Clinical and biological significance of
Cdk10 in hepatocellular carcinoma. Gene. 498:68–74. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kasten M and Giordano A: Cdk10, a
Cdc2-related kinase, associates with the Ets2 transcription factor
and modulates its transactivation activity. Oncogene. 20:1832–1838.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC and Ambros V: An extensive class of
small RNAs in Caenorhabditis elegans. Science. 294:862–864. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yates LA, Norbury CJ and Gilbert RJ: The
long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu X, Zhu Y, Liang Z, Li S, Xu X, Wang X,
Wu J, Hu Z, Meng S, Liu B, et al: c-Met and CREB1 are involved in
miR-433-mediated inhibition of the epithelial-mesenchymal
transition in bladder cancer by regulating Akt/GSK-3β/Snail
signaling. Cell Death Dis. 7:e20882016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang XC, Ma Y, Meng PS, Han JL, Yu HY and
Bi LJ: miR-433 inhibits oral squamous cell carcinoma (OSCC) cell
growth and metastasis by targeting HDAC6. Oral Oncol. 51:674–682.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weiner-Gorzel K, Dempsey E, Milewska M,
McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A,
Sharpe D, et al: Overexpression of the microRNA miR-433 promotes
resistance to paclitaxel through the induction of cellular
senescence in ovarian cancer cells. Cancer Med. 4:745–758. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Z, Tsuchiya H, Zhang Y, Hartnett ME
and Wang L: MicroRNA-433 inhibits liver cancer cell migration by
repressing the protein expression and function of cAMP response
element-binding protein. J Biol Chem. 288:28893–28899. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo LH, Li H, Wang F, Yu J and He JS: The
tumor suppressor roles of miR-433 and miR-127 in gastric cancer.
Int J Mol Sci. 14:14171–14184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Furlong F, Fitzpatrick P, O'Toole S,
Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe
M, McGoldrick A, et al: Low MAD2 expression levels associate with
reduced progression-free survival in patients with high-grade
serous epithelial ovarian cancer. J Pathol. 226:746–755. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kroh EM, Parkin RK, Mitchell PS and Tewari
M: Analysis of circulating microRNA biomarkers in plasma and serum
using quantitative reverse transcription-PCR (qRT-PCR). Methods.
50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 50:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Tekcham DS and Tiwari PK: Non-coding RNAs
as emerging molecular targets of gallbladder cancer. Gene.
588:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oliveto S, Mancino M, Manfrini N and Biffo
S: Role of microRNAs in translation regulation and cancer. World J
Biol Chem. 8:45–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu J, Zhang W, Tang H, Qian H, Yang J, Zhu
Z, Ren P and Lu B: Septin 2 accelerates the progression of biliary
tract cancer and is negatively regulated by mir-140-5p. Gene.
589:20–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Williams TM, Majithia L, Wang SJ and
Thomas CR Jr: Defining the role of adjuvant therapy:
Cholangiocarcinoma and gall bladder cancer. Semin Radiat Oncol.
24:94–104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Phelip JM, Vendrely V, Rostain F, Subtil
F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, et
al: Gemcitabine plus cisplatin versus chemoradiotherapy in locally
advanced biliary tract cancer: Fédération Francophone de
Cancérologie Digestive 9902 phase II randomised study. Eur J
Cancer. 50:2975–2982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Yang L, Shuai T, Piao T and Wang R:
miR-433 inhibits retinoblastoma malignancy by suppressing Notch1
and PAX6 expression. Biomed Pharmacother. 82:247–255. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang T, Guo Q, Li L, Cheng Y, Ren C and
Zhang G: MicroRNA-433 inhibits migration and invasion of ovarian
cancer cells via targeting Notch1. Neoplasma. 63:696–704. 2016.
View Article : Google Scholar : PubMed/NCBI
|
